Chemotherapy plus dose-escalated radiation shows promise for advanced NSCLC: study
Chemoradiation with stereotactic ablative radiotherapy boost seems to enhance local control but with reduced overall survival at highest dose.
Chemoradiation with an adaptive stereotactic ablative radiotherapy boost is safe and effective for patients with locally advanced, unresectable non-small cell lung cancer, according to a study in JAMA Oncology.
US researchers from the University of California, Los Angeles examined the maximum tolerated dose and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost among patients with clinical stage II or III non-small cell lung cancer (NSCLC).
